Risultati di ricerca
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
- Careers
We drive innovation to defeat some of the most complex and...
- Pipeline
With a strong focus on difficult-to-treat diseases, our...
- Disease Areas
Biogen is dedicated to enhancing the lives of those with SMA...
- Science & Innovation
Biogen has pioneered the development of multiple sclerosis...
- Medicines
Below is a list of our company's therapies. The below...
- Company
Founded in 1978, Biogen has pioneered multiple breakthrough...
- Lupus
Biogen’s decades of study at the crossroads of neurology and...
- Multiple Sclerosis
Over the past four decades, Biogen has been committed to...
- Careers
Biogen è un’azienda globale leader nel settore delle biotecnologie e pioniera di numerose innovazioni medico-scientifiche nelle aree della neurologia, immunologia e malattie rare.
Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Biogen Italia è un’azienda molto attenta a promuovere la Qualità, elemento funzionale e necessario a migliorare continuamente le dinamiche aziendali e, più in generale, a garantire la giusta attenzione dell’Azienda ai bisogni dei pazienti e della Comunità Scientifica.
7 giu 2021 · Il farmaco, chiamato “Aduhelm” e prodotto dalla società farmaceutica Biogen, “rappresenta, infatti, il primo trattamento approvato per l'Alzheimer sin dal 2003”, ha affermato la FDA.
With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
